Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Key claim: The DEA finalizes regulations implementing the SUPPORT Act and Restoring Hope Act provisions governing practitioner eligibility and pharmacy delivery rules for medication-assisted treatment of opioid use disorder.
Abstract
(Rule · Justice Department, Drug Enforcement Administration) The “Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (the SUPPORT Act),” which became law on October 24, 2018, amended the Controlled Substances Act to expand the conditions a practitioner must meet to provide medication-assisted treatment for opioid use disorder and expand the options available for a physician to be considered a qualifying physician. The SUPPORT Act also allowed a pharmacy to deliver prescribed controlled substances to a practitioner’s registered location for the purpose of maintenance or detoxification treatment to be administered under certain conditions by a practitioner. The Drug Enforcement Administration promulgated an interim final rule with request for comments in November 2020 to amend its regulations to make them consistent with the SUPPORT Act and implement its requirements. On December 29, 2022, the Restoring Hope for Mental Health and Well-Being Act of 2022 removed many of the statutory provisions of the SUPPORT Act. This final rule adopts the provisions of the interim final rule that are still applicable as final, with minor changes. In addition, this final rule implements the related provisions of the Restoring Hope for Mental Health and Well-Being Act of 2022.
Why this matters
The final rule sets the operational federal rules for how buprenorphine and methadone can be prescribed, dispensed, and delivered for opioid use disorder treatment — directly affecting which clinicians can treat OUD patients and how pharmacies and opioid treatment programs handle these medications. For patients, providers, and pharmacies, codification into DEA regulation converts statutory MAT reforms into enforceable compliance obligations. It marks the DEA’s implementation catch-up on MAT access provisions Congress enacted years earlier.